Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer

Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer


Kenvue, a unit of Johnson & Johnson’s consumer health business.

CFOTO | Future Publishing | Getty Images

Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer.

J&J owns 89.6% of Kenvue’s common stock, which amounts to more than 1.72 billion shares. 

related investing news

We're selling some shares of this health-care company and changing our rating

CNBC Investing Club

The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue’s common stock at a 7% discount. The offer is expected to be tax-free, J&J said in a release. 

The company noted that the split-off is voluntary for investors and is slated to close on Aug. 18, which is far earlier than expected.

J&J said it received a waiver that dismisses the share lockup period associated with Kenvue’s initial public offering in May. That lockup agreement would have required J&J to wait 180 days to sell any of its shares. 

“We believe now is the right time to distribute our Kenvue shares, and we are confident that a split-off is the appropriate path forward to bring value to our shareholders,” J&J CEO Joaquin Duato said in a statement. 

Duato added that the split-off will sharpen J&J’s focus on its pharmaceutical and medtech businesses – both of which helped the company beat on second-quarter revenue and adjusted earnings last week. 

J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. Shares of Kenvue fell following that announcement, despite second-quarter results that also topped Wall Street estimates. 

When asked about J&J’s planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC’s “Squawk on the Street” that the company is “pleased with the way that the IPO has been received by shareholders.”

“We see a lot of alignment among our new investors in seeing the potential of Kenvue, but I can tell you that we are fully ready to leave as a fully independent company,” he said. 



Source

Kennedy sidesteps vaccine questions: ‘I don’t think people should be taking medical advice from me’
Health

Kennedy sidesteps vaccine questions: ‘I don’t think people should be taking medical advice from me’

Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday sidestepped a question about vaccines and whether he would choose to vaccinate his children today against a number of diseases, saying, “I don’t think people should be taking medical advice from me.” Kennedy’s comment was in response to Rep. Mark Pocan, D-Wis., during a […]

Read More
Healthy Returns: Trump provides a glimpse of the third round of Medicare drug price negotiations
Health

Healthy Returns: Trump provides a glimpse of the third round of Medicare drug price negotiations

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York City. Spencer Platt | Getty Images News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to […]

Read More
FDA moves to take prescription fluoride drops and tablets for kids off the market
Health

FDA moves to take prescription fluoride drops and tablets for kids off the market

Ferlistockphoto | Istock | Getty Images The Food and Drug Administration on Tuesday announced it will begin the process of pulling prescription fluoride drops and tablets for children off the market. The supplements are usually given to kids at high risk for cavities. The federal government and some state legislatures are increasingly drawing attention to what they […]

Read More